Neuromodulation through Brain Stimulation-assisted Cognitive Training in Patients with Post-Chemotherapy Cognitive Impairment (Neuromod-PCCI): Study Protocol of a Randomized Controlled Trial

5

- 6 Merle Rocke^{1*}, Elena Knochenhauer^{1*}, Friederike Thams¹, Daria Antonenko¹, Anna
- 7 Elisabeth Fromm¹, Nora Jansen¹, Ulrike Grittner^{2,3}, Sein Schmidt⁴, Eva-Lotta
- 8 Brakemeier⁵, Agnes Flöel^{1,6}
- 9

10 Affiliations:

- ¹ Department of Neurology, Universitätsmedizin Greifswald, Ferdinand-Sauerbruch-
- 12 Straße, 17475 Greifswald, Germany
- ² Berlin Institute of Health (BIH), at Charité Universitätsmedizin Berlin, Charitéplatz
- 14 1, 10117 Berlin, Germany
- ³ Institute of Biometry and Clinical Epidemiology, Charité Universitätsmedizin
- 16 Berlin, Charitéplatz 1, 10117, Berlin, Germany
- ⁴ Department of Neurology and Experimental Neurology, Charité-Universitätsmedizin
- 18 Berlin, Berlin, Germany
- ⁵ Department of Psychology and Psychotherapy, Universität Greifswald, Franz-
- 20 Mehring-Str. 47, 17489 Greifswald, Greifswald, Germany
- ⁶ German Centre for Neurodegenerative Diseases (DZNE) Standort Greifswald,
- 22 Greifswald, Germany
- 23
- 24 * contributed equally
- 25
- 26 Corresponding author:
- 27 Agnes Flöel, MD
- 28 University Medicine Greifswald
- 29 Department of Neurology
- 30 Ferdinand-Sauerbruch-Straße,
- 31 D-17475 Greifswald
- 32 E-mail: agnes.floeel@med.uni-greifswald.de
- 33 Phone: +49-3834-86-6815
- 34 Fax: +49-3834-86-6875
- 35
- 36 Emails: merle.rocke@stud.uni-greifswald.de; elena.knochenhauer@uni-
- 37 greifswald.de; friederike.thams@uni-greifswald.de; daria.antonenko@med.uni-
- 38 greifswald.de; anna.fromm@med.uni-greifswald.de; nora.jansen@med.uni-
- 39 greifswald.de; ulrike.grittner@charite.de; sein.schmidt@charite.de; eva-
- 40 <u>lotta.brakemeier@uni-greifswald.de;</u> agnes.floeel@med.uni-greifswald.de
- 41
- 42 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

43 Abstract

Introduction: Breast cancer is the most common form of cancer in women. A 44 considerable number of women with breast cancer who have been treated with 45 46 chemotherapy, subsequently develop neurological symptoms such as concentration 47 and memory difficulties (also known as 'chemobrain'). Currently, there are no validated therapeutic approaches available to treat these symptoms. Cognitive 48 49 training holds the potential to counteract cognitive impairment. Combining cognitive training with concurrent transcranial direct current stimulation (tDCS) could enhance 50 and maintain the effects of this training, potentially providing a new approach to treat 51 post-chemotherapy cognitive impairment (PCCI). With this study, we aim to 52 investigate the effects of multi-session tDCS over the left dorsolateral prefrontal 53 cortex in combination with cognitive training on cognition and guality of life in women 54 with PCCI. 55 Methods and analysis: The Neuromod-PCCI trial is a monocentric, randomized, 56 57 double-blind, placebo-controlled study. Fifty-two women with PCCI after breast 58 cancer therapy will receive a 3-week tDCS-assisted cognitive training with anodal tDCS over the left dorsolateral prefrontal cortex (target intervention), compared to 59 60 cognitive training plus sham tDCS (control intervention). Cognitive training will consist of a letter updating task. Primary outcome will be the performance in an untrained 61 62 task (n-back task) after training. In addition, feasibility, safety and tolerability, as well as quality of life and performance in additional untrained tasks will be investigated. A 63 64 follow-up visit will be performed one month after intervention to assess possible longterm effects. In an exploratory approach, structural and functional magnetic 65 66 resonance imaging (MRI) will be acquired before the intervention and at postintervention to identify possible neural predictors for successful intervention. 67 Ethics and dissemination: Ethical approval was granted by the ethics committee of 68 the University Medicine Greifswald (BB236/20). Results will be available through 69 publications in peer-reviewed journals and presentations at national and international 70 71 conferences. *Trial registration:* This trial was prospectively registered at ClinicalTrials.gov 72 73 (Identifier: NCT04817566, registered March 26, 2021). 74 Keywords: transcranial direct current stimulation, working memory, transfer, 75

76 executive function, quality of life

Stre	ngth and limitations of this study
-	This is the first randomized controlled trial to investigate the feasibility and
	effects of combined cognitive training and tDCS on cognitive outcomes and
	quality of life in patients with post-chemotherapy cognitive impairment
-	Results will help the development of treatment options for breast cancer
	patients with post-chemotherapy cognitive impairment
-	Results may not be generalizable to male cancer patients
	Management of the later is a second
-	Monocentric trial design may increase risk of bias
	-

90 Introduction

91 With the development of new treatment options, the long-term survival rates of breast

- 92 cancer patients is increasing ¹. However, cancer patients may develop cognitive
- ⁹³ impairments following chemotherapy ²³. Post-chemotherapy cognitive impairment
- 94 (PCCI), also referred to as "chemobrain", can persist for many years after
- 95 chemotherapy and occurs in various cognitive domains, such as executive functions,
- 96 memory, processing speed, and attention ^{3 4}. Beyond that, cognitive impairment may
- 97 cause psychological distress and affect quality of life ⁵⁻⁸.
- 98 The pathophysiology of PCCI remains poorly understood. Multiple mechanisms
- 99 underlying patterns of cognitive impairment in cancer patients have been proposed,
- 100 including neuroinflammation, direct neurotoxicity, as well as alterations in structure,
- 101 function and metabolic profile of the brain ⁹ as well as changes in neurotransmitters,
- such as reduced concentrations of norepinephrine, dopamine and serotonin, among
- 103 others ¹⁰.

104 Thus far, no evidence-based treatment options are available. First studies have 105 found preliminary evidence that cognitive training may improve cognitive abilities of patients with PCCI ¹¹⁻¹³. Von Ah et al. observed an improvement in trained functions 106 107 and a transfer effect to untrained memory tasks as well as to self-rated subjective 108 cognitive function, and reduced psychological stress in the trained group compared 109 to a waiting list control group after training of memory and speed of processing ¹². Similarly, in the study of Kesler et al. participants trained cognitive flexibility, working 110 memory, processing speed and verbal fluency, and subsequently showed enhanced 111 performance in cognitive functions meditated by the prefrontal cortex as well as 112 minor improvements in declarative memory scores¹³. Despite these promising 113 preliminary findings, training programs have been time-intensive, involving several 114 115 weeks of task practice, and transfer effects have not consistently been demonstrated 14 116

- 117 Non-invasive brain stimulation is an approach to boost training gains, which allows
- 118 for shorter training periods and for induction of transfer to untrained functions.
- 119 Transcranial direct current stimulation (tDCS) is an inexpensive, painless method that
- is well-tolerated, safe and easy to apply ¹³. This promising approach is already widely

used for interventional and therapeutic purposes (see ^{15 for review}). For administration of 121 122 tDCS, a weak electric current is applied via two or more electrodes on the 123 participant's scalp. The supposed mechanism of action is a directional modulation of the cortical excitability in the brain area under the electrodes as well as in functionally 124 125 and structurally connected brain regions ¹⁶. The application of direct current causes a shift in the resting membrane potential of the cortical neurons which in turn leads to a 126 decrease of the threshold for triggering action potentials. Accordingly, the 127 corresponding area of the brain shows a higher level of excitability. Furthermore, the 128 129 excitatory effect of anodal stimulation leads to an increase in synaptic transmission, which can last for hours to days. This effect corresponds to long-term potentiation-130 like mechanism and can induce neural plasticity ¹⁷. Promising results of the technique 131 with regard to improving cognitive performance have been demonstrated in healthy 132 133 aging, but also in patients with dementia or mild cognitive impairment (MCI)^{18 19}. 134 To our knowledge, no study to date has examined the effects of tDCS-assisted 135 cognitive training in patients with PCCI in order to establish its potential to beneficially impact cognitive functions and patient-reported outcome measures such as health-136 137 related quality of life (HRQoL). In the Neuromod-PCCI study, we plan to assess in a 138 double-blind randomized controlled phase II clinical trial if such a combined multi-139 session cognitive training plus tDCS intervention yields substantial long-term benefits and transfer effects in patients with PCCI. All patients will complete cognitive training 140 141 of a letter updating task over nine training sessions with concurrent tDCS over the left dorsolateral prefrontal cortex (dIPFC). Half of the sample will receive anodal tDCS 142 143 while performing the cognitive training, whereas the other half will undergo sham stimulation during training. The intervention will span three weeks, with three training 144 sessions per week. We will assess behavioral outcome measures, such as direct 145 146 training effects, feasibility, safety and tolerability, transfer to untrained domains, and 147 long-term effects on cognition and quality of life at multiple time points. We will further 148 elucidate neural characteristics associated with interventional success before the 149 intervention and assess neural correlates at post-intervention. This protocol, describing the design and methods of the Neuromod-PCCI study, was prepared in 150 accordance with the SPIRIT guidelines ^{20 21} 151

153 Methods: Participants, Intervention, and Outcomes

154

155 Design and Setting

- 156 This is a monocentric, randomized, double-blind, placebo-controlled study. The
- 157 intervention is comprised out of nine sessions of cognitive training over three weeks,
- accompanied by anodal tDCS over the left dIPFC compared to sham tDCS. Subjects
- 159 will participate in 13 sessions altogether with pre- and post-intervention assessments.
- 160 One follow-up session is planned one month after the intervention to assess possible
- 161 long-term effects. All sessions will take place at the University Medicine Greifswald,
- 162 Greifswald, Germany. Magnetic resonance imaging (MRI) will be performed before
- the intervention and at post-intervention ("add-on" study, i.e. optional for the
- 164 participants). A flowchart of the study is shown in **Figure 1**.
- 165




Figure 1: Neuromod-PCCI study flowchart. MRI, magnetic resonance imaging. tDCS, transcranial direct current stimulation. ZPP, Zentrum für Psychologische Psychotherapie (university psychotherapy outpatient clinic).

170 Eligibility Criteria

- Participants included in the study must meet all of the following inclusion criteria: 171
- Chemotherapy to treat breast cancer (over 6 months since end of treatment) 172
- Self-reported concerns regarding cognitive function 173 •
- 174 • Age: 18-65 years
- Right-handedness 175
- 176
- In case one or more of the following criteria are present at randomization, potential 177 participants will be excluded: 178
- 179 • History of dementia before treatment of cancer
- Other neurodegenerative neurological disorders, epilepsy or a history of 180 • 181 seizures
- Severe and untreated medical conditions that preclude participation in the 182 183 training, as determined by responsible physician
- History of moderate to severe substance use disorder according to DSM-5²² 184 •
- Moderate to severe acute mental disorders according to DSM-5²² 185 •
- Contraindication to tDCS ²³ 186 •
- 187

Note that contraindication to MRI will not be treated as exclusion criteria as 188 participants will still be included in the study sample, but no MRI scans will be

189

190 performed in these individuals. If all eligibility criteria are met and participants provide

191 written informed consent, they will be included in the study sample.

192

193 Intervention

194 At each of the training sessions participants will receive either anodal or sham tDCS 195 while completing a cognitive training task. Before starting the training task, the scalp of the participants will be numbed via an application of a topical anesthetic (EMLA® 196 197 Cream, 25mg/g Lidocain + 25 mg/g Prilocain). The EMLA cream will be applied on 198 the scalp according to the positioning of the electrodes and will be left to take effect 199 for about 20 min. After the exposure time, the EMLA cream will be removed, the 200 tDCS setup will be mounted and stimulation will be started. 201

Participants will be presented with a letter updating (LU) task on a tablet computer to
train working memory updating. List of letters A to D (with lengths of 5, 7, 9, 11, 13 or
15 letters, six times each; total of 36 lists) will be presented in random order, one
letter at a time (presentation duration 2000 ms, ISI 500 ms). After each list
participants will be asked to recall the last four letters that were presented.

TDCS will be administered via a battery-operated stimulator (Neuroelectrics Starstim 208 8, Barcelona, Spain). A current of 2 mA will be applied via five round electrode-gel 209 210 filled NG PigStim electrodes (NE029, Neuroelectrics, Barcelona, Spain), connected 211 to the stimulator and mounted in a neoprene head cap using the 10-20 EEG grid. 212 The stimulation will be applied continuously for 20 min, with 20 additional sec of 213 ramping at the beginning and at the end of stimulation, respectively. The anodal 214 electrode will be placed over the left dIPFC (F3). The four cathodal electrodes will be arranged in a circle around the anodal electrode, in the positions of AFz, F7, C5 and 215 FCz respectively, to constrain the current flow to the target region. In the sham 216 group, current will be applied for 30 sec to blind the participants regarding their 217 218 stimulation condition. Ramp times and electrode montage will be the same as in the 219 anodal group. The cognitive training task and the stimulation will be started 220 simultaneously. After every third session, participants will fill out an adverse-events questionnaire ²³. Participants will be instructed to avoid excessive consumption of 221 222 alcohol or nicotine on the days of intervention. Moreover, they will be asked to adhere to their regular sleep schedule and to avoid drinking caffeine 90 min prior to 223 224 the training sessions.

225

226 Outcome Measures

227

228 Primary Outcomes

Primary outcome measure will be working memory performance at post-assessment,
operationalized by the percentage of correct responses in the n-back task (untrained
task).

232

233 Secondary Outcomes

234 Secondary outcome will be working memory performance in the untrained task

235 (nback, ²⁴) at follow-up assessment, operationalized by the percentage of correct

responses. Additionally, performance in primary memory training task (LU task, ²⁵) 236 and visuospatial memory performance (virtual reality (VR) task, ²⁶) will be assessed 237 238 at post- and follow-up-assessments. Performance in the training task will be operationalized by number of correctly recalled lists in the LU task and visuospatial 239 240 performance will be operationalized by number of correctly recalled items in the VR 241 task. Further secondary outcome measures include Quality of Life, operationalized via the 242 PROMIS Preference score (PROPr score) which serves as a summary scoring 243 244 system of health-related quality of life including domains such as depression, fatigue, pain interference and ability to participate in social roles and activities²⁷. The domain 245 246 of cognitive function will be scored separately because it is the most important 247 subscale for this study. Scoring will be carried out according to the scoring manuals 248 (http://www.healthmeasures.net/). Feasibility will be operationalized through drop-out rates (% participants that did not complete post-assessment), adherence rates of 249 250 training sessions (number of training sessions attended) and the post-study system usability questionnaire (PSSUQ)²⁸, completed by study assessors. Additionally, 251 252 structural and functional neural correlates (assessed at pre- and post-assessments), 253 as measured by structural and functional MRI, will be assessed.

254

255 Exploratory Analyses

Exploratory analyses will be conducted for more detailed outcomes of the training task (e.g., outcomes dependent on list length in the LU task). Additionally, education, baseline cognitive ability or neuropsychological status as well as socio-demographic and clinical characteristics will be analyzed to identify potential predictors of training task performance and response to the intervention.

261

262 Participant Timeline

Individuals will participate in 13 visits, and two optional MRI sessions, taking place at
the University Medicine Greifswald. After inclusion at baseline visit (V0), participants
will attend the pre-assessment visit (V1) before starting the nine training visits during
three consecutive weeks on three days a week (V2-V10). After the training, a postassessment (V11) will be conducted and four weeks later a follow-up visit (V12) will

- 268 be administered. MRI will be acquired before pre-assessment (V1) and at post-
- assessment (V13).

270 Baseline Measures

At baseline, participants will provide written informed consent and participate in a 271 demographic interview. The participants will be asked to provide a record of their 272 273 cancer specific medical history. If study-relevant information is missing, it will be 274 requested from the responsible physician. Furthermore, a diagnostic interview to screen for mental disorders will be conducted and subsequently the participants will 275 276 be tested with a comprehensive battery of neuropsychological tests to quantify cognitive function on different domains. The following interviews, questionnaires and 277 278 tests will be conducted:

- Diagnostic interview for mental disorders (semi-structured diagnostic interview, DIPS)²⁹ to screen amongst others for moderate to severe acute mental disorders according to DSM-5 ²² including depression, anxiety
- 282 disorders, post-traumatic stress disorder and sleep disorders
- Childhood Trauma Screener (CTS)³⁰ to screen for childhood mal-treatment
- German version of the Auditory verbal learning test (AVLT)^{24 31} to test verbal
 memory
- Rey-Osterrieth Complex Figure Test (ROCF)³² to test visual-spatial memory
- Digit Span ²⁴ and Trail Making Test A/B (TMT A/B)³³ to test short term/working
 memory
- Stroop test ^{24 34} and Semantic word fluency test ²⁴ to test executive functions Afterwards, participants will perform the training task as described above, with the exception that at baseline the task will consist of one practice trail with 4 lists and one actual training trial with 25 lists (compared to 36 lists in the training). The baseline assessment will have an approximated duration of 3,5h.
- 294

An actigraph (GT3X, ActiGraph, Pensacola, FL, USA) will be handed out to the
participants at baseline to record sleep and activity data. Participants will be
instructed to wear the device in the week leading up to pre-assessment and in the
week following the post-assessment. Additionally, at baseline, participants will be
asked to complete two sleep questionnaires: the Epworth Sleepiness Scale to
measure daytime sleepiness ³⁵ and the Morningness-Eveningness-Questionnaire ³⁶
to estimate the participant's circadian rhythm.

303 Pre-, Post-, and Follow-Up-Assessments

All three sessions will follow the same procedure. First, self-reported well-being, 304 305 quality and duration of sleep as well as potential stressors up to two hours prior to the 306 visit will be assessed by the investigator via a questionnaire. The participants will 307 further complete an array of QoL-related questionnaires: Patient Reported Outcomes Measure System (PROMIS®) which evaluates physical, mental and social health ²⁷ 308 and the EORTC QLQC30 which assesses the quality of life in cancer patients, 309 supplemented with the module EORTC BR23 with the focus on breast cancer ³⁷. To 310 311 further complete the data assessment regarding sleep, the Pittsburgh Quality Sleep Index ³⁸ will be administered to assess sleep guality over a longer interval. Then, 312 313 participants will complete the training task and untrained tasks. The follow-up 314 assessments will provide the possibility for assessing the maintenance of training 315 and transfer effects.

316

317 Sample Size

Power calculation is based on recent studies using multi-session application of 318 319 cognitive training compared to a control training on immediate performance in the trained task (primary outcome) ³⁹⁻⁴¹. Based on these data, we estimated an effect 320 321 size of 0.8 (Cohen's d). To demonstrate an effect in the primary outcome between 322 cognitive training groups and control (% correct in the n-back task for the anodal vs. sham stimulation group) with an independent t-test using a two-sided significance 323 level of α = 0.05 and a power of at least 80 %, 52 participants (26 for target 324 intervention group, 26 for control intervention group) need to be included. This 325 326 conservative approach using a t-test was chosen for sample size estimation, even though we intend to analyze the primary outcome conducting an analysis of 327 covariance (ANCOVA) model ⁴². This monocentric clinical trial will serve to calculate 328 sample size for a subsequent multicenter clinical trial. Sample size estimation was 329 330 conducted using R software (http://www.R-project.org) and the pwr package 331 (https://cran.r-project.org/package=pwr).

332

333 Recruitment

- 334 The participants will be recruited by the distribution of flyers at the university
- 335 psychotherapy outpatient clinic (Zentrum für Psychologische Psychotherapie) and at
- 336 local psychotherapeutic doctor's offices in Greifswald and surroundings.

- 337 Furthermore, we will search for participants via articles and announcements in the
- local newspaper. Telephone screenings assessing inclusion and exclusion criteria
- 339 will be conducted with all potential participants and study information will be provided.
- 340 Eligible participants will be invited for baseline assessment.
- 341

342 Methods: Assignment of Interventions

- Allocation of the participants to the experimental groups will be performed by a 343 researcher not involved in the study. Participants will be randomly allocated in a 1:1 344 345 ratio to the two groups (anodal vs. sham tDCS). Baseline performance in the n-back task will be used as strata (two performance strata; ≤ 87 % correct and > 87 % 346 347 correct in the n-back task). Randomization blocks with varying block sizes will be generated for each of the two stimulation groups, using R software (https://www.R-348 349 project.org) and the blockrand package (http://CRAN.R-350 project.org/package=blockrand). Participants will then be allocated to the anodal or
- sham tDCS group based on the generated randomization sequences within eachblock and stratum.
- 353

354 Blinding

As this is a double-blind trial, participants and investigators will be blinded regarding 355 the stimulation condition. In the sham group the current will be applied for 30s to 356 357 blind the participants to the intervention. In previous studies, sham tDCS has been shown as a safe and valid method of blinding participants ⁴³⁻⁴⁶. At the end of the nine-358 session intervention, participants will be asked to state if they believe they received 359 360 anodal or sham stimulation. As for the investigator blinding, a staff member who is not involved in this project will perform the randomization according to the procedure 361 362 described above and provide unidentifiable labels for the two stimulation protocols 363 (anodal, sham). The investigator involved in this study will select the protocol that 364 corresponds to the participants ID number and will be able to apply the stimulation accordingly without knowledge of the respective stimulation condition. 365

366 Methods: Data Collection, Management, and Analysis

367 Data Collection Methods

368 Neuropsychological, behavioral and sleep data will be collected from each

369 participant. Study investigators will be thoroughly trained in administering the

- 370 assessments. Additionally, participants will receive an in-depth training on the
- 371 handling of the Actigraph so that they can adequately and safely administer the sleep
- recording on their own. The questionnaires that are handed out to the participants will
- 373 be explained by an investigator and will be accompanied by additional written
- instruction on how and when to complete the questionnaire. Time points and
- 375 methods of data collection are shown in **Table 1**. MRI data will be collected for
- individuals participating in the "add-on" MRI study (optional) unless there are
- 377 contraindications to MRI scanning.
- 378

Table 1. Neuromod-PCCI outcome measures.

			Baseline	Pre	T1-T9 (3 weeks)	Post (3 days)	FU (1 month)
			~3h	~2h	~1h	~2h	~2h
Time point	Measurement	Mode	V0	V1	V2-V10	V11	V12
Enrollment							
Eligibility screening		Paper	х				
Informed consent		Paper	х				
Neuropsychological Screening	Demographic data	Paper	х				
	CTS ³⁰	Paper	х				
	AVLT ³¹	Paper	х				
	Digit Span ²⁴	Paper	х				
	Stroop ³⁴	Paper	х				
	TMT A/B ³³	Paper	х				
	ROCF ³²	Paper	х				
Quality of Life	PROMIS ²⁷	Paper		х		х	Х
	EORTC QLQ C30 ³⁷	Paper		х		х	х
	EORTC BR2337	Paper		х		х	Х

Sleep data	Epworth Sleepiness Scale ³⁵	Paper	х				
	Pittsburgh Sleep Quality Index ³⁸	Paper		x		х	
	Morningness- Eveningness- Questionnaire ³⁶	Paper	х				
	Actigraph	Device		х		х	
ntervention					\leftrightarrow		
Training task	Letter updating ²⁵	Tablet- Computer	x	Х	x	x	х
Brain stimulation	tDCS (anodal vs. sham)	Device			х		
Questionnaires	Self-reported well-being	Paper		х	х	Х	х
	PANAS ⁴⁸	Paper			Х		
	Adverse events questionnaire ^{23*}	Paper			х		
Additional assessm	nents						
Untrained tasks	n-back (primary outcome) ²⁴	Computer		х		х	х
	Virtual reality task ²⁶	Computer		х		х	х
Physical measures	MRI, optional			х		х	
easibility	Adherence rates	Paper			х	x	

Abbreviations: T1-T9, training 1-9; FU, follow-up-assessment; V0-V12, visits 0-12; CTS, childhood trauma
screener; AVLT, German version of the auditory verbal learning test; TMT A/B, trail making test A/B; ROCF, ReyOsterrieth complex figure test; PROMIS, patient reported outcomes measurement system; EORTC QLQ
C3/BR23, European organization for research and treatment of cancer, quality of life questionnaire (QLQ C30),
supplemented with the extension regarding breast cancer specific quality of life (BR23); tDCS, transcranial direct
current stimulation; PANAS, positive and negative affect schedule; MRI, magnetic resonance imaging. All
measures were acquired on site, except for screening which was done via telephone. *assessed only at the end
of each training week (V4, V7 and 10).

387

388 Neuropsychological Assessment

389 Neuropsychological tests at baseline visit (V0) comprise paper-pencil as well as

390 computer-based assessments. Performance in several cognitive domains will be

tested with the auditory verbal learning test^{24 31}, the Digit Span²⁴, the Stroop test^{24 34},

the Trail Making Test A/B ³³, and the Rey-Osterrieth Complex Figure Test ³².

Trained and untrained tasks include paper-pencil and computer-based assessments. 393 394 Detailed description of the training task is provided in the interventions section. At 395 pre-, post- and follow-up sessions (V1, V11 and V12) the untrained tasks will be 396 administered: Participants will perform a numeric n-back task (1 and 2 back) and a 397 VR navigation task ²⁶. The n-back (1-and 2-back) task will be administered as an untrained task to assess working memory function (18 trials total, 9 trials 1 back and 9 398 trials 2back with 10 items each, presentation duration 1500 ms, ISI 2500 ms). The 399 participants will have to state for a sequence of numerical digits presented one after 400 401 the other, if the stimulus that is presented currently is the same stimulus as "n"-steps 402 back. The participants will answer via a keypress, left arrow key for "yes" if the stimuli match and right arrow key for "no" if the stimuli differ. This task requires that different 403 404 brain functions are coordinated effectively including updating, discrimination and matching of the stimuli and decision making ^{24 49}. The VR task ²⁶ will be administered 405 as a untrained task. Here, during encoding, participants will be instructed to 406 407 memorize a route with several targets (e.g., butcher, doctor's office and grocery 408 store); during subsequent recall, the participants will be asked to navigate the 409 shortest route to given targets.

410

411 Psychological Assessment

A variety of questionnaires will be administered over the course of the study. At 412 413 baseline visit (V0) the participants will be screened for childhood maltreatment and 414 various mental disorders via the CTS ³⁰ and the DIPS ²⁹. The CTS is a 5-item questionnaire regarding experiences of neglect and abuse in childhood and 415 adolescence. The DIPS is an established diagnostic interview which helps to 416 417 thoroughly explore different possible mental diagnoses. It guides the interviewer, covering the different aspects of each disorder, the degree of symptom expression, 418 419 and subsequently aids in classifying the possible mental disorders according to DSM-420 5.

421 At pre-, post- and follow-up assessment the following Quality of Life questionnaires422 will be administered:

- Patient Reported Outcomes Measure System (PROMIS®, https://promis germany.de/) to assess physical, mental and social health
- EORTC QLQC30³⁷, to measure QoL of cancer patients

- EORTC BR23, which is a module of the EORTC QLQ C30 and focuses on
 the mental and physical health of breast cancer patients
- 428 Simultaneously with the collection of sleep data through actigraphy, the participants
- 429 will be asked to fill in three questionnaires regarding their sleep quality and rhythm.
- 430 The Morningness-Eveningness-Questionnaire ³⁶ and the Epworth Sleepiness Scale
- ³⁵ will be administered at Baseline assessment, the Pittsburg Sleep Index ³⁸ will be
- administered both at pre-and post-assessment, assessing day-time sleepiness,
- 433 quality of sleep and the sleep rhythm of the participants in the last month/weeks.
- 434

435 Magnetic resonance imaging

MRI will be acquired at the Baltic Imaging Center (Center for Diagnostic Radiology 436 437 and Neuroradiology, Universitätsmedizin Greifswald) with a 3-Tesla scanner 438 (Siemens Verio) using a 32-channel head coil, prior to the training intervention and at post-intervention. A T1-weighted 3D sequence, a 3D FLAIR, a diffusion tensor imaging 439 (DTI), single-voxel magnetic resonance spectroscopy (MRS) and a resting-state fMRI 440 sequence will be recorded. Additional T1- and T2-weighted structural images will be 441 acquired with parameters optimized for computational modeling to calculate electric 442 field distributions (simnibs.org) ^{50 51}. Seed-based resting-state functional connectivity 443 444 within and between large-scale task-relevant networks (e.g., frontoparietal and default 39 52 53 445 mode network) will be performed using the CONN toolbox 446 (www.nitrc.org/projects/conn) ⁵⁴. White-matter pathways will be reconstructed from 55 diffusion-weighted TRACULA 447 images using pipeline in Freesurfer (http://surfer.nmr.mgh.harvard.edu/), in order to extract tract fractional anisotropy and 448 449 mean diffusivity ⁵⁶⁻⁵⁹. Changes in FA and MD on whole-brain level will be analyzed using FSL's tract-based spatial statistics (TBSS, www.fmrib.ox.ac.uk/fsl)^{60 61}. MD in 450 gray matter will also be explored for examination of intervention-induced 451 microstructural gray matter change ⁶². Quantifications of metabolite concentrations 452 (such as N-acetylaspartate, glutamate, and gamma-aminobutyric acid, among others) 453 454 in the MRS voxel will be extracted using software packages in Matlab (The Mathworks Inc., Natick; MA). Segmentation on high-resolution T1 scans will be performed to 455 assess the volume of cortical and subcortical gray matter ^{25 63} using the computational 456 http://www.neuro.unijena.de/cat/) and 457 anatomy toolbox (CAT12, Freesurfer 458 (http://surfer.nmr.mgh.harvard.edu/).

460 Retention and Adherence

To ensure adherence and retention throughout the entire study period, participants 461 462 will be contacted regularly via telephone or email and will be provided with information about their appointments. A few days prior to the intervention, a member of the study 463 464 team will call the participant to remind them of the upcoming appointments and to check if there are any open questions to address. Additionally, the participants will be 465 provided with a document listing all their appointments with notes regarding parking 466 and caffeine consumption at pre-assessment. At the end of each visit, the participants 467 468 will be reminded of the date and time of the next session. Throughout the whole study 469 period participants will be encouraged to contact the 24/7 study answer machine if 470 questions or concerns arise. Similarly, they will be prompted to leave a voice message if they are unable to attend or wish to reschedule a session. They then will be 471 472 contacted to discuss alternative scheduling or to address possible questions and concerns. At the end of the study, participants will receive a reasonable financial 473 474 reimbursement (approximately 10 € per hour) and the results of their neuropsychological screening and, if they underwent MRI scanning, their structural 475 476 MRI images on a compact disc. If complete adherence to the protocol is not possible, 477 any effort to collect as much data as possible will be made.

478

479 Data Management and Monitoring

All participant data will be pseudonymized. Spreadsheets containing both participant 480 481 IDs and personal data will be protected with a password only known to the study staff 482 and will be stored on a secure file server. Similarly, digital data, i.e. output files from 483 computer-based tasks, will be saved on a secure file server directly after acquisition. Non-digitally acquired data will be manually digitalized by a staff member of the 484 485 research team and double-checked by another member. Progress of data entry and checking procedures will be documented. Files containing subject records will be 486 487 sorted by participant ID and stored securely. Sensitive data, such as names and 488 medical records, will be scored separately in lockable cabinets in rooms with access 489 restricted to the researchers. Protocols of the tDCS setup of each participant and 490 session will also be stored on the file server and MRI data will be pseudonymized 491 before analysis. Following good scientific practice, data will be stored for at least 10 492 years.

493 Adverse Events Monitoring

Safety and tolerability will be assessed through monitoring any potentially occurring 494 adverse events (AEs) via an adverse events questionnaire ²³, administered at the 495 end of each training week (V4, V7 and V10). We will refrain from administering the 496 497 AE questionnaire at every visit, since this would possibly draw the participant's 498 attention to minor sensations during the stimulation and would only serve as a distraction from the training task. Generally, adverse events during tDCS are rare 499 and minimal. Known AEs with the applied stimulation parameters (20min, 2mA) are 500 501 skin reddening, a tingling sensation under the electrode sites and occasionally a mild headache ²³. As we will be using a local anesthetic under the electrode sites, we 502 expect even less noticeable sensations ^{64 65}. Investigators will be instructed to 503 504 monitor AEs and serious AEs (SAEs) throughout the study and document all 505 detected AEs and SAEs. Participants will be informed at baseline assessment about 506 all possible AEs and risks and can withdraw their consent at any time without providing reason. In case a SAE occurs, the study physician will first make an 507 508 assessment as to whether a causal relationship with the intervention is considered plausible. If more than three of the enrolled participants suffer from SAEs likely to be 509 510 associated with the intervention (as assessed by the study physician), the trial will be 511 discontinued.

512 Statistical Methods

The primary outcome, percent of correct responses in the n-back task at post-513 514 compared to the pre-training assessment will be analyzed using ANCOVA with postassessment n-back performance as dependent variable, pre-assessment n-back 515 516 performance as covariate, and group allocation (target intervention (n=26) vs. control 517 intervention (n=26)) as independent variable. Linear mixed models will be conducted for secondary outcomes with experimental group as between-subjects factor. All 518 models will be corrected for age and performance at pre-assessment. We will use 519 520 random intercept models that account for the clustering of measures within individuals. In case of violation of requirements for parametric methods, data will be 521 522 transformed before analysis. Analyses of primary and secondary outcomes will be reported in detail in the statistical analysis plan to be written and registered before 523 unblinding of investigators performing the analyses. Confirmatory analysis of 524 525 treatment effects will be conducted within an intention to treat (ITT) framework with

multiple imputed data sets in case of missing data (under the assumption of missing 526 527 completely at random or missing at random). Further as sensitivity analyses, we will 528 perform "per protocol" analyses, including only those participants who finished postassessment. Feasibility data (% drop-out rate and number of attended training 529 530 sessions per participant) will be analyzed using descriptive statistics. Data distributions of the feasibility questionnaire items will be visually assessed for 531 normality using q-q plots, and statistically using the Shapiro-Wilk test ^{66 67}. 532 Data analysis will be conducted using IBM SPSS Statistics for Windows (IBM Corp., 533 534 Armonk, NY), MatLab (The Mathworks Inc., 2016), and R software (https://www.Rproject.org). 535

536

537 Patient and public involvement

538 We will conduct a brief semi-structured interview at the last visit (V12) to assess the 539 patients' satisfaction with the trial and answer any upcoming questions. The patients 540 were not involved in designing the intervention. All patients will be informed about the 541 study details (e.g. the experimental group they participated in) upon completion of the 542 study.

543 Ethics and Dissemination

The study was approved by the ethics committee of the University Medicine of
Greifswald and will be conducted in accordance with the Helsinki Declaration. All
data collected will be pseudonymized. Results of the study will be made accessible to
scientific researchers and health care professionals via publications in peer reviewed
journals and presentations at national and international conferences. Furthermore,
the scientific and lay public can access the study results on the ClinicalTrails.gov
website (Identifier: NCT04817566).

551 Conclusion

With this trial, we will for the first time investigate the immediate and long-term effects as well as the feasibility, safety and tolerability of a combined training and brain stimulation intervention on trained (working memory) performance and transfer to other domains as well as on health-related quality of life in patients with postchemotherapy cognitive impairment. The results of this trial will contribute to the development of non-invasive interventions for a condition affecting everyday lives of many breast cancer patients.

559 Protocol amendments

- 560 Any substantial amendment to the study protocol will be submitted to the Institutional
- 561 Ethics Committee for review and approval.

562 **Consent or assent**

- 563 A member of the investigational team (study coordinator or study assessor) will
- 564 collect written informed consent during study enrollment after having reviewed the
- 565 participant information sheet, participant's questions, and study inclusion and
- 566 exclusion criteria.

567 Confidentiality

- 568 The collected data will be treated as confidential. Direct access to personal
- 569 information and source data documentation will only be given to study monitors,
- 570 study assessors, and the research team.

571 Availability of data and materials

- 572 Anonymized data will be made available to the scientific community upon request.
- 573 Ethics approval and consent to participate
- 574 This study was approved by the ethics committee of the University Medicine
- 575 Greifswald, Germany (BB236/20), date of first approval: 5 January 2021). All
- 576 procedures conducted during the Neuromod-PCCI trial will be carried out in
- 577 compliance with the Declaration of Helsinki.
- 578 **Authors' Contributions:** AF, DA, and ELB conceptualized and designed this trial.
- 579 AF and DA are supervising its implementation. AEF and DA are implementing the
- trial and supervising its conduct. MR, NJ and EK are performing recruitment and
- assessments. MR, EK, and FT drafted the study protocol. UG, DA and AEF will be
- 582 performing statistical analyses. All authors will be contributing to the interpretation of
- the data. All authors read and revised the original draft and consecutive versions of
- the manuscript. All authors read and approved the final version of the study protocol.
- 585 **Competing interests**
- 586 The authors declare no actual or potential conflicts of interest.
- 587 **Funding**
- 588 The authors have not declared a specific grant for this research from any funding
- 589 agency.
- 590

591 **References**

- 592 1. Kaplan HG, Malmgren JA, Atwood MK, et al. Effect of treatment and
 593 mammography detection on breast cancer survival over time: 1990-2007:
 594 Improved Breast Ca Survival Over Time. *Cancer* 2015;121(15):2553-61. doi:
 595 10.1002/cncr.29371
- 596 2. Mounier NM, Abdel-Maged AE-S, Wahdan SA, et al. Chemotherapy-induced
 597 cognitive impairment (CICI): An overview of etiology and pathogenesis. *Life* 598 *Sciences* 2020;258:118071. doi: 10.1016/j.lfs.2020.118071
- 599 3. Vitali M, Ripamonti CI, Roila F, et al. Cognitive impairment and chemotherapy: a
 brief overview. *Critical Reviews in Oncology/Hematology* 2017;118:7-14. doi:
 10.1016/j.critrevonc.2017.08.001
- 4. Collins B, MacKenzie J, Tasca GA, et al. Cognitive effects of chemotherapy in
 breast cancer patients: a dose-response study. *Psycho-Oncology*2013;22(7):1517-27. doi: 10.1002/pon.3163
- 5. Boykoff N, Moieni M, Subramanian SK. Confronting chemobrain: an in-depth look
 at survivors' reports of impact on work, social networks, and health care
 response. *Journal of Cancer Survivorship* 2009;3(4):223. doi:
- 608 10.1007/s11764-009-0098-x
- 609 6. Reid-Arndt SA, Yee A, Perry MC, et al. Cognitive and Psychological Factors
 610 Associated with Early Posttreatment Functional Outcomes in Breast Cancer
 611 Survivors. Journal of Psychosocial Oncology 2009;27(4):415-34. doi:
 612 10.1080/07347330903183117
- 7. Von Ah D, Habermann B, Carpenter JS, et al. Impact of perceived cognitive
 impairment in breast cancer survivors. *European Journal of Oncology Nursing* 2013;17(2):236-41. doi: 10.1016/j.ejon.2012.06.002
- 8. Wefel JS, Kesler SR, Noll KR, et al. Clinical characteristics, pathophysiology, and
 management of noncentral nervous system cancer-related cognitive
 impairment in adults: Cancer-Related Cognitive Impairment. *CA: A Cancer Journal for Clinicians* 2015;65(2):123-38. doi: 10.3322/caac.21258
- 9. Han R, Yang YM, Dietrich J, et al. Systemic 5-fluorouracil treatment causes a
 syndrome of delayed myelin destruction in the central nervous system. *Journal of biology* 2008;7(4):12. doi: 10.1186/jbiol69 [published Online First:
 2008/04/24]
- 10. Seigers R, Schagen SB, Van Tellingen O, et al. Chemotherapy-related cognitive
 dysfunction: current animal studies and future directions. *Brain imaging and behavior* 2013;7(4):453-9. doi: 10.1007/s11682-013-9250-3 [published Online
 First: 2013/08/21]
- 11. Poppelreuter M, Weis J, Bartsch HH. Effects of Specific Neuropsychological
 Training Programs for Breast Cancer Patients After Adjuvant Chemotherapy.
 Journal of Psychosocial Oncology 2009;27(2):274-96. doi:
 10.1080/07347330902776044
- Von Ah D, Carpenter JS, Saykin A, et al. Advanced cognitive training for breast
 cancer survivors: a randomized controlled trial. *Breast Cancer Research and Treatment* 2012;135(3):799-809. doi: 10.1007/s10549-012-2210-6
- Kesler S, Hadi Hosseini SM, Heckler C, et al. Cognitive training for improving
 executive function in chemotherapy-treated breast cancer survivors. *Clin Breast Cancer* 2013;13(4):299-306. doi: 10.1016/j.clbc.2013.02.004 [published
 Online First: 2013/05/08]
- 14. Park DC, Bischof GN. The aging mind: neuroplasticity in response to cognitive
 training. *Dialogues in Clinical Neuroscience* 2013;15(1):109-19.

- 641 15. Filmer HL, Dux PE, Mattingley JB. Applications of transcranial direct current
 642 stimulation for understanding brain function. *Trends in Neurosciences*643 2014;37(12):742-53. doi: 10.1016/j.tins.2014.08.003
- 644 16. Stagg CJ, Nitsche MA. Physiological basis of transcranial direct current
 645 stimulation. *The Neuroscientist: A Review Journal Bringing Neurobiology,* 646 *Neurology and Psychiatry* 2011;17(1):37-53. doi: 10.1177/1073858410386614
- 647 17. Brem A-K, Ran K, Pascual-Leone A. Learning and memory. *Handbook of Clinical* 648 *Neurology* 2013;116:693-737. doi: 10.1016/B978-0-444-53497-2.00055-3
- 18. Prehn K, Flöel A. Potentials and limits to enhance cognitive functions in healthy
 and pathological aging by tDCS. *Frontiers in Cellular Neuroscience* 2015;9
 doi: 10.3389/fncel.2015.00355
- In Simerman M, Nitsch M, Giraux P, et al. Neuroenhancement of the aging brain:
 Restoring skill acquisition in old subjects. *Annals of Neurology* 2013;73(1):10 Io. 1002/ana.23761
- 20. Chan A-W, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining
 standard protocol items for clinical trials. *Annals of internal medicine*2013;158(3):200-07.
- 658 21. Chan A-W, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and 659 elaboration: guidance for protocols of clinical trials. *Bmj* 2013;346:e7586.
- 22. Association AP. Diagnostic and Statistical Manual of Mental Disorders. Fifth
 Edition ed: American Psychiatric Association 2013.
- Antal A, Alekseichuk I, Bikson M, et al. Low intensity transcranial electric
 stimulation: Safety, ethical, legal regulatory and application guidelines. *Clinical Neurophysiology* 2017;128(9):1774-809. doi:
 https://doi.org/10.1016/j.clinph.2017.06.001
- 24. Lezak MD, Howieson DB, Bigler ED, et al. Neuropsychological Assessment. 5th
 edition ed. Oxford ; New York: Oxford University Press 2012.
- 25. Dahlin E, Neely AS, Larsson A, et al. Transfer of learning after updating training
 mediated by the striatum. *Science (New York, NY)* 2008;320(5882):1510-2.
 doi: 10.1126/science.1155466 [published Online First: 2008/06/17]
- 67126. Hartley T, Maguire EA, Spiers HJ, et al. The Well-Worn Route and the Path Less672Traveled. Neuron 2003;37(5):877-88. doi: 10.1016/s0896-6273(03)00095-3
- 673 27. Cella D, Choi SW, Condon DM, et al. PROMIS® adult health profiles: efficient
 674 short-form measures of seven health domains. *Value in health*675 2019;22(5):537-44.
- 28. Lewis JR. Psychometric Evaluation of the PSSUQ Using Data from Five Years of
 Usability Studies. International Journal of Human–Computer Interaction
 2002;14(3-4):463-88. doi: 10.1080/10447318.2002.9669130
- 679 29. Margraf J, Čwik JC, Suppiger A, et al. DIPS Open Access: Diagnostisches
 680 Interview bei psychischen Störungen. 2017 doi: 10.13154/RUB.100.89
- 30. Grabe H, Schulz A, Schmidt C, et al. Ein Screeninginstrument für Missbrauch
 und Vernachlässigung in der Kindheit: der Childhood Trauma Screener (CTS). *Psychiatrische Praxis* 2012;39(03):109-15. doi: 10.1055/s-0031-1298984
- 684 31. Helmstaedter C, Lendt M, Lux S. Verbaler Lern-und Merkfähigkeitstest: VLMT;
 685 Manual: Beltz-Test 2001.
- 32. Meyers JE, Meyers KR. Rey Complex Figure Test and Recognition Trial. 1.
 Auflage ed. Göttingen: Hogrefe 1995.
- 33. Strauss E, Sherman EMS, Spreen O. A Compendium of Neuropsychological
 Tests: Administration, Norms, and Commentary. 3. Edition ed. Oxford ; New
 York: Oxford University Press 2006.

34. Stroop JR. Studies of interference in serial verbal reactions. Journal of 691 experimental psychology 1935;18(6):643. 692 693 35. Johns MW. A New Method for Measuring Daytime Sleepiness: The Epworth 694 Sleepiness Scale. *Sleep* 1991;14(6):540-45. doi: 10.1093/sleep/14.6.540 36. Horne JA, Ostberg O. A self-assessment questionnaire to determine 695 696 morningness-eveningness in human circadian rhythms. International Journal 697 of Chronobiology 1976;4(2):97-110. 37. Fayers P, Bottomley A. Quality of life research within the EORTC-the EORTC 698 699 QLQ-C30. European Journal of Cancer 2002;38:125-33. doi: 10.1016/S0959-700 8049(01)00448-8 38. Buysse DJ, Reynolds CF, Monk TH, et al. The Pittsburgh sleep guality index: A 701 702 new instrument for psychiatric practice and research. Psychiatry Research 1989;28(2):193-213. doi: 10.1016/0165-1781(89)90047-4 703 704 39. Antonenko D, Kulzow N, Sousa A, et al. Neuronal and behavioral effects of multi-705 day brain stimulation and memory training. *Neurobiology of aging* 706 2018;61:245-54. doi: 10.1016/j.neurobiolaging.2017.09.017 [published Online 707 First: 2017/10/21] 708 40. Park SH, Seo JH, Kim YH, et al. Long-term effects of transcranial direct current 709 stimulation combined with computer-assisted cognitive training in healthy older 710 adults. Neuroreport 2014;25(2):122-6. doi: 10.1097/WNR.00000000000000080 [published Online First: 2013/11/02] 711 41. Jones K. Stephens J. Alam M. et al. Longitudinal neurostimulation in older adults 712 713 improves working memory. PloS one 2015; 10(4). https://www.cochranelibrary.com/central/doi/10.1002/central/CN-714 715 01215335/full. 42. Borm GF, Fransen J, Lemmens WA. A simple sample size formula for analysis of 716 717 covariance in randomized clinical trials. Journal of clinical epidemiology 718 2007;60(12):1234-38. 719 43. Floel A, Cohen LG. Recovery of function in humans: Cortical stimulation and 720 pharmacological treatments after stroke. Neurobiology of Disease 721 2010;37(2):243-51. doi: 10.1016/j.nbd.2009.05.027 44. Gandiga PC, Hummel FC, Cohen LG. Transcranial DC stimulation (tDCS): A tool 722 for double-blind sham-controlled clinical studies in brain stimulation. Clinical 723 724 *Neurophysiology* 2006;117(4):845-50. doi: 725 https://doi.org/10.1016/j.clinph.2005.12.003 45. Kuo HI, Bikson M, Datta A, et al. Comparing cortical plasticity induced by 726 conventional and high-definition 4×1 ring tDCS: a neurophysiological study. 727 728 Brain stimulation 2013;6(4):644-8. doi: 10.1016/j.brs.2012.09.010 [published 729 Online First: 2012/11/15] 730 46. Schlaug G, Renga V. Transcranial direct current stimulation: a noninvasive tool to facilitate stroke recovery. Expert review of medical devices 2008;5(6):759-68. 731 732 47. Passow S, Thurm F, Li S-C. Activating Developmental Reserve Capacity Via 733 Cognitive Training or Non-invasive Brain Stimulation: Potentials for Promoting 734 Fronto-Parietal and Hippocampal-Striatal Network Functions in Old Age. Frontiers in Aging Neuroscience 2017;9:33. doi: 10.3389/fnagi.2017.00033 735 736 48. Watson D, Clark LA, Tellegen A. Development and validation of brief measures 737 of positive and negative affect: the PANAS scales. Journal of personality and 738 social psychology 1988;54(6):1063. 49. Sweet LH. N-Back Paradigm. In: Kreutzer JS, DeLuca J, Caplan B, eds. 739 740 Encyclopedia of Clinical Neuropsychology. New York, NY: Springer 741 2011:1718-19.

- 50. Windhoff M, Opitz A, Thielscher A. Electric field calculations in brain stimulation
 based on finite elements: an optimized processing pipeline for the generation
 and usage of accurate individual head models. *Human brain mapping*2013;34(4):923-35.
- 51. Field modeling for transcranial magnetic stimulation: A useful tool to understand
 the physiological effects of TMS? 2015 37th Annual International Conference
 of the IEEE Engineering in Medicine and Biology Society (EMBC); 2015 25-29
 Aug. 2015.
- 52. Antonenko D, Hayek D, Netzband J, et al. tDCS-induced episodic memory
 enhancement and its association with functional network coupling in older
 adults. *Scientific Reports* 2019;9 doi: 10.1038/s41598-019-38630-7
- 53. Darki F, Klingberg T. The role of fronto-parietal and fronto-striatal networks in the
 development of working memory: a longitudinal study. *Cereb Cortex*2015;25(6):1587-95. doi: 10.1093/cercor/bht352 [published Online First:
 2014/01/15]
- 54. Whitfield-Gabrieli S, Nieto-Castanon A. Conn: a functional connectivity toolbox for
 correlated and anticorrelated brain networks. *Brain connectivity* 2012;2(3):12541.
- 55. Yendiki A, Panneck P, Srinivasan P, et al. Automated probabilistic reconstruction
 of white-matter pathways in health and disease using an atlas of the
 underlying anatomy. *Frontiers in neuroinformatics* 2011;5:23.
- 56. Le Bihan D, Johansen-Berg H. Diffusion MRI at 25: exploring brain tissue
 structure and function. *Neuroimage* 2012;61(2):324-41.
- 57. Metzler-Baddeley C, Jones DK, Belaroussi B, et al. Frontotemporal connections
 in episodic memory and aging: a diffusion MRI tractography study. *Journal of Neuroscience* 2011;31(37):13236-45.
- 58. Metzler-Baddeley C, Foley S, de Santis S, et al. Dynamics of White Matter
 Plasticity Underlying Working Memory Training: Multimodal Evidence from
 Diffusion MRI and Relaxometry. *J Cogn Neurosci* 2017;29(9):1509-20. doi:
 doi:10.1162/jocn a 01127 [published Online First: 2017/03/31]
- 59. Charlton RA, Barrick TR, Lawes INC, et al. White matter pathways associated with working memory in normal aging. *Cortex* 2010;46(4):474-89.
- 60. Jenkinson M, Beckmann CF, Behrens TE, et al. Fsl. *Neuroimage* 2012;62(2):782-90.
- 61. Smith SM, Jenkinson M, Woolrich MW, et al. Advances in functional and
 structural MR image analysis and implementation as FSL. *Neuroimage*2004;23:S208-S19.
- 62. Brodt S, Gais S, Beck J, et al. Fast track to the neocortex: A memory engram in
 the posterior parietal cortex. *Science (New York, NY)* 2018;362(6418):104548.
- Filmer HL, Ehrhardt SE, Shaw TB, et al. The efficacy of transcranial direct current
 stimulation to prefrontal areas is related to underlying cortical morphology.
 NeuroImage 2019;196:41-48. doi: 10.1016/j.neuroimage.2019.04.026
- 64. Guarienti F, Caumo W, Shiozawa P, et al. Reducing transcranial direct current
 stimulation-induced erythema with skin pretreatment: considerations for sham controlled clinical trials. *Neuromodulation: Journal of the International Neuromodulation Society* 2015;18(4):261-65. doi: 10.1111/ner.12230
- 65. McFadden JL, Borckardt JJ, George MS, et al. Reducing Procedural Pain and
 Discomfort Associated with Transcranial Direct Current Stimulation. *Brain stimulation* 2011;4(1):38-42. doi: 10.1016/j.brs.2010.05.002

- 66. Rahbek MA, Mikkelsen EE, Overgaard K, et al. Exercise in myasthenia gravis: A
 feasibility study of aerobic and resistance training. *Muscle & Nerve*2017;56(4):700-09. doi: https://doi.org/10.1002/mus.25552
- 67. Bock BC, Thind H, Fava JL, et al. Feasibility of yoga as a complementary therapy
 for patients with type 2 diabetes: The Healthy Active and in Control (HA1C)
 study. Complement Ther Med 2019;42:125-31. doi:
- 798 10.1016/j.ctim.2018.09.019 [published Online First: 2018/09/26]